Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Millipore and Oxford Immunotec co-develop plates for diagnosing and monitoring infections

Billererica, MA, USA and Oxford, UK, 21 September 2005 - Millipore Corporation (NYSE:MIL) and Oxford Immunotec Ltd. announced today the co-development of a specially designed microtitre plate for use in clinical diagnostics kits. The new plate further advances the simplicity, cost-effectiveness and performance of Oxford Immunotec's proprietary T-SPOT(tm) technology.

This is the first 8-well strip-based plate customised for use in Enzyme-Linked Immunospot (ELISPOT) methodology compared with typical 96-well plates. It is more economical for users to select the number of wells they require and reduce waste as a result. Utilizing Millipore's market-leading ELISPOT technology with Immobilon®-P membrane, users can rely on the quality and accuracy of the product.

Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec commented, 'We have been consistently impressed by Millipore as a collaboration partner. They have delivered a state-of-the art product on time and on budget. Pairing our pre-eminent T-SPOT technology for diagnosing and monitoring infectious diseases with a flexible multi-well platform is a key step forward in integrating this test worldwide.'

Oxford Immunotec will incorporate the plate into a second generation of its T-SPOT.TB test kit, a revolutionary new test for tuberculosis. It is set to replace the 100-year old skin test currently used to diagnose this resurgent disease. Incorporating the new plate will provide greater flexibility and improved performance, while lowering the cost of administering the test.

'Millipore is committed to aligning itself with technology leaders, such as Oxford Immunotec, for the delivery of leading-edge products,' said Jonathan DiVincenzo, Vice President of R&D and Marketing for Millipore's Bioscience Division. 'The first use of the new plate is a test that will greatly improve the control of one of the world's most profound health problems.'

The two companies entered into this partnership in September 2004. Currently, the plates are in production. Under the terms of the agreement, Oxford Immunotec has exclusive rights to use the plates for in vitro diagnostics with its T-SPOT assay kits.

About Oxford Immunotec
Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT technology, which opens up new ways of diagnosing and monitoring infections. T-SPOT is a simple and extremely accurate method of studying a person's cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T-cell response.

About T-SPOT(tm).TB
T-SPOT.TB is an in vitro T-cell activation assay used for diagnosing TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe and is designed to replace the 115 year old tuberculin skin test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market of £600m.

About Millipore Corporation
Millipore is a leading bioprocess and bioscience products and services company, organized into two divisions. The Bioprocess Division offers solutions that optimize development and manufacturing of biologics. The Bioscience Division provides high performance products and application insights that improve laboratory productivity. Millipore has a deep understanding of its customers' research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company employs approximately 4,500 people worldwide and posted revenues of $883 million in 2004. For more information about Millipore visit

Publisher Contact Information:

Oxford Immunotec Ltd.
+44 (0)1235 442780

Company profile of Oxford Immunotec Ltd.
Past press releases of Oxford Immunotec Ltd..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.